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Abstract
With the completion of the human genome sequence, biomedical sciences have entered in the ‘‘omics’’ era, mainly due to
high-throughput genomics techniques and the recent application of mass spectrometry to proteomics analyses. However,
there is still a time lag between these technological advances and their application in the clinical setting. Our work is
designed to build bridges between high-performance proteomics and clinical routine. Protein extracts were obtained from
fresh frozen normal lung and non-small cell lung cancer samples. We applied a phosphopeptide enrichment followed by LC-
MS/MS. Subsequent label-free quantification and bioinformatics analyses were performed. We assessed protein patterns on
these samples, showing dozens of differential markers between normal and tumor tissue. Gene ontology and interactome
analyses identified signaling pathways altered on tumor tissue. We have identified two proteins, PTRF/cavin-1 and MIF,
which are differentially expressed between normal lung and non-small cell lung cancer. These potential biomarkers were
validated using western blot and immunohistochemistry. The application of discovery-based proteomics analyses in clinical
samples allowed us to identify new potential biomarkers and therapeutic targets in non-small cell lung cancer.
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Introduction
Lung cancer is the leading cause of cancer death in the world.
The overall survival rate at 5 years is 15% and has not been
improved for decades. Two thirds of patients are diagnosed with
advanced disease where therapeutic options are palliative, and up
to 55% of patients with limited disease eventually relapse after
radical surgery [1].
Gene expression profiling has led to the identification of groups of
patients with different outcome, thus reflecting the heterogeneity of
this disease [2]. However, gene-level analyses do not detect subtle
changes caused by post-translational modifications of proteins [3]. A
deep understanding of the processes of carcinogenesis, tumor
progression and metastasis requires the analysis of both the genome
and the proteome [4]. Proteomic technologies based on mass
spectrometry (MS) have emerged as preferred components of a
strategy to discover diagnostic, prognostic and therapeutic protein
biomarkers [5]. Continuing advances in this field give this strategy
an enormous potential for such investigations [6,7].
Recent clinical trials demonstrating good response to new
drugs in specific subgroups of patients underline the need for
molecular tests that complement classical histopathological
procedures [8]. In this context, proteomic profiling can provide
valuable biomarker tools for efficient patient stratification and
therapy selection.
Although it is possible to analyze proteins from tissues using
mass spectrometry [3,9], the complexity of the clinical sample and
the amount of available protein are limiting factors. Therefore,
sample enrichment in biologically relevant analytes is required [5].
Most eukaryotic cellular processes are regulated by protein
phosphorylation, and deregulation of this key post-translational
modification is common in cancer and other diseases. This
explains why protein kinases have emerged as the main class of
new drug targets in oncology and other fields [10]. In this work we
have applied phosphopeptide enrichment coupled with label-free
MS techniques to identify already known and new potential
biomarkers in non-small cell lung cancer clinical tissues and
validate them using western blot and immunohistochemistry.
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Materials and Methods
Ethics statement
Institutional approval from our ethical committee was obtained
for the conduct of the study (Comite´ E´tico de Investigacio´n
Clı´nica, Hospital Universitario La Paz). Data were analyzed
anonymously. Patients provided written consent so that their
samples and clinical data could be used for investigational
purposes.
Sample selection
Frozen samples from patients diagnosed with lung cancer were
retrieved from the Department of Pathology of Hospital
Universitario La Paz (Madrid, Spain): 5 lung adenocarcinoma
(AC), 5 lung squamous cell carcinoma (SC) and 5 normal lung
(NL) samples. The histopathological features of each sample were
reviewed by an experienced lung pathologist to confirm diagnosis
and tumor content. At least 50% of a sample had to be made up of
tumor cells for it to be eligible. Samples from patients were kindly
provided by the IdiPAZ Biobank (RD09/0076/00073) integrated
in the Spanish Hospital Biobanks Network (RetBioH; www.
redbiobancos.es). Samples were registered and processed following
current procedures and fixed/frozen immediately after their
reception.
Total protein extraction, solubilization and digestion
Samples were cut in a Leica CM3050S cryostat, obtaining 10
sections of 10 microns thickness each. Tissue was processed with
TRIzol reagent (Invitrogen) following the manufacturer’s instruc-
tions. For MS analyses, protein pellets were resuspended in
guanidine hydrochloride 6 M and heated 10 minutes at 95uC with
agitation. Subsequently, 950 ml of 50 mM ammonium bicarbon-
ate (pH 7–9) per sample were added. Protein sample concentra-
tion was measured by MicroBCA Protein Assay Kit (Pierce-
Thermo Scientific). Trypsin MS Grade Gold (Promega) was added
to each sample to a 1:50 relation. Digestion was carried out
overnight at 37uC. The digested sample was divided into two
aliquots.
Parallel IMAC (PIMAC)
Phosphopeptide enrichment was carried out as described
previously [11]. Briefly, Fe(III)-based IMAC was performed in
one aliquot of digested protein using the PHOS-Select Iron
Affinity Gel (Sigma-Aldrich) following the manufacturer’s instruc-
tions. Ga(III)-based IMAC was performed in another aliquot of
digested protein using the Phosphopeptide Isolation Kit (Pierce-
Thermo Scientific) following the manufacturer’s instructions.
Eluates were mixed, vacuum-dried and stored at 220uC for later
MS analysis.
LC-MS/MS analyses
Peptide mixtures were subjected to nano-liquid chromatogra-
phy coupled with MS for protein identification. Peptides were
injected into a C-18 reversed phase (RP) nano-column (100 mm
I.D. and 12 cm, Mediterranea sea, Teknokroma) and analyzed in
a continuous acetonitrile gradient consisting of 0–40% B in
90 min, 50–90% B in 20 min (B = 95% acetonitrile, 0.5% acetic
acid). At the end of the gradient, the column was washed with 90%
B and equilibrated with 5% B for 20 min. A flow rate of 300 nl/
min was used to elute peptides from the RP nano-column to an
emitter nanospray needle for real time ionization and peptide
fragmentation on an LTQ-Orbitrap XL mass spectrometer
(Thermo-Fisher). An enhanced FT-resolution spectrum (resolu-
tion = 60000) followed by the MS/MS spectra from the five most
intense parent ions were analyzed along the chromatographic run
(130 min). Dynamic exclusion was set at 1 min. For protein
identification fragmentation spectra were searched against the
MSDB database (version 091509) using the Mascot 2.1 program
(Matrixscience). Two missed cleavages were allowed, and an error
of 10 ppm or 0.8 Da was set for full MS or MS/MS spectra
searches, respectively. All identifications were performed by
Proteome Discoverer 1.0 software (Thermo-Fisher). Decoy
database search for false discovery rate analysis was set at 0.05
by applying corresponding filters. Raw data files were processed
and compared with SIEVE version 1.2 (Thermo-Fisher). Protein
identifications were validated using the BLAST tool from the
blastp suite (http://blast.ncbi.nlm.nih.gov). For detailed peptide
mass fingerprint and protein identification settings, see Table S4.
Inmunoblotting assays
For inmunoblotting assays, protein pellets were resuspended in
2% SDS and heated 10 minutes at 95uC with agitation. Protein
sample concentration was measured by MicroBCA Protein Assay
Kit (Pierce-Thermo Scientific).Western blots were performed
using WesternDot system (Invitrogen) in a SNAP i.d. device
(Millipore). MIF antibody 1: 250 dilution (R&D Systems) and
PTRF antibody 1:125 dilution (BD Biosciences) were used.
Densitometry analyses were performed using ImageJ 1.38e
software (http://rsb.info.nih.gov/ij/) to measure the intensity of
bands. For western blot normalization, total protein loading was
measured using the Novex Reversible Membrane Stain Kit
(Invitrogen).
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue blocks, representative
of normal lung and non-small cell lung cancer diagnosis, were
retrieved following routine histopathological assessment. Sections
were processed using a Dako Autostainer universal staining system
(Dako). For this study, 3.5-mm sections were immunostained with
anti-MIF 1:2000 (R&D Systems) or anti-PTRF 1:100 (BD
Biosciences). Images were obtained in a Leyca microscope with
magnification640. The percentage of stained tissue and the stain
intensity (0, +, ++ or +++) was obtained for each sample and
marker evaluated. IHC staining was considered positive when at
least 50% of the tissue (normal or tumoral) was stained with at
least ++.
Statistical Analyses
Expression values between sample groups were compared using
a Kruskal-Wallis test (Gaussian Approximation). To assess
differences between pairs of groups Dunn’s Multiple Comparison
Test was used. A p-value,0.05 was considered significant. SIEVE
and densitometry values were compared using Pearson’s correla-
tion coefficient.
Bioinformatics
Protein lists were processed using The Database for Annotation,
Visualization and Integrated Discovery (DAVID) version 2.0
(http://david.abcc.ncifcrf.gov/home.jsp) [12,13]. To identify un-
der- and over-represented functional categories we used Protein
ANalysis THrough Evolutionary Relationships (PANTHER)
database v 6.1 (www.pantherdb.org) [14]. Tumor protein list
were compared to the normal lung list using the binomial test [15]
for each molecular function, biological process or pathway term in
PANTHER. Protein-protein interactions were obtained from the
Search Tool for the Retrieval of Interacting Genes/Proteins
(STRING) database v9.0 containing known and predicted physical
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and functional protein-protein interactions [16]. STRING in
protein mode was used, and only interactions based in
experimental protein-protein interaction and curated databases-
with confidence levels over 0.5- were kept.
Results
In this study, we assessed differences at the protein level between
non-small cell lung cancer (NSCLC) and lung normal tissue using
a phosphopeptide enrichment strategy and a label-free approach.
Samples were analyzed on a LTQ-Orbitrap XL after being
subjected to liquid chromatography. Since it is known that
different techniques isolate distinct and overlapping segments of
the phosphoproteome [17], including Fe(III) and Ga(III) IMAC
[18], we mixed the Fe(III) and Ga(III) IMAC fractions from each
sample and analyzed them together.
We evaluated the number of unique peptides and their
corresponding proteins, as well as phosphopeptides and their
corresponding phosphoproteins, identified in lung adenocarcino-
ma (AC), lung squamous cell carcinoma (SC) and normal lung
(NL) samples applying a decoy database search at false discovery
rate,0.05. The extensive analysis performed in NSCLC and NL
samples using LC-MS/MS allowed us to identify a mean of 381
unique peptides per sample, of which a mean of 56 were
phosphopeptides. These peptides corresponded to a mean of 138
unique proteins identified per sample, of which a mean of 39 were
phosphorylated. The fraction of phosphopeptides identified
(number of phosphorylated peptides*100/number of identified
peptides) was 19.9%.
Gene ontology analyses were performed using all identified
proteins. The tumor protein list was compared to the normal lung
protein list for each molecular function (Figure S1), biological
process (Figure S2), or pathway (Figure 1) terms using PANTHER.
This approach showed significant differences between normal lung
and tumor samples (complete analyses are provided in Table S1).
Differences in molecular functions are mainly related to the
interaction with nucleic acids and the regulation of protein
synthesis and activity. Processes controlling exocytosis, immune
response, response to stimulus, response to stress and transport
were significantly under-represented in tumors, whereas categories
related to cell-matrix adhesion or response to toxin were over-
represented. On the other hand, homeostasis categories were
under-represented, whereas categories related with energy pro-
duction and cell proliferation were over-represented in tumors.
Remarkable differences in pathway analysis appeared in categories
related with signal transduction control. While cytoskeletal
regulation by Rho GTPase, inflammation mediated by chemokine
and cytokine signaling pathway, integrin signaling pathway and
Wnt signaling pathway were under-represented in tumor samples,
EGF receptor signaling pathway, Glycolysis, p53 pathway and PI3
kinase pathway were over-represented.
Differential expression analysis between NSCLC vs. normal
lung was performed using SIEVE 1.2 software. A total of 296
differentially expressed m/z peaks were found, 115 of which had
available MS2 spectra, leading to the identification of proteins
differentially expressed between normal lung and NSCLC samples
(Table 1). All data obtained from SIEVE analyses, including
relative expression values, are provided in Table S2.
PTRF/cavin-1 and MIF outstand among the differentially
expressed biomarkers between NSCLC and normal lung samples
in label-free analyses as the most down-regulated and up-regulated
respectively (Figure 2). PTRF/cavin-1 showed loss of expression in
both adenocarcinoma and squamous cell carcinoma samples. On
the other hand, MIF showed an increased expression in these
Figure 1. Analysis of differences in GO Pathways between NSCLC and normal lung. Comparison of number of proteins assigned to each
GO pathway category. Normal tissue sample categories are represented as fold-change in relation to this category. Statistical significance is tested
using the binomial test. Only significant categories (p,0.05) are shown.
doi:10.1371/journal.pone.0033752.g001
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Table 1. Differentially expressed peptides.
Peptide m/z GeneID Gene Symbol
Ratio
TvsN P Value
Peptides down-regulated in tumor samples
FKDLGEENFK 409.54 213 ALB 0.55 0.039
VLSPADKTNVK 586.34 3040 HBA2 0.10 0.016
VGAHAGEYGAEALER 765.37 3040 HBA2 0.19 0.000
TYFPHFDLSHGSAQVK 917.45 3040 HBA2 0.26 0.000
TYFPHFDLSHGSAQVK 611.97 3040 HBA2 0.33 0.000
EFTPQVQGAFQK 690.36 3043 HBB 0.23 0.010
VVAGVANALAHKYH 725.40 3043 HBB 0.24 0.003
VLGAFSDGLAHLDNLK 835.45 3043 HBB 0.24 0.019
LHVDPENFR 563.79 3043 HBB 0.25 0.008
VVAGVANALAHK 575.34 3043 HBB 0.29 0.003
KVLGAFSDGLAHLDNLK 600.00 3043 HBB 0.29 0.005
VNVDEVGGEALGR 438.89 3043 HBB 0.32 0.000
VNVDEVGGEALGR 657.84 3043 HBB 0.33 0.000
VLGAFSDGLAHLDNLK 557.30 3043 HBB 0.34 0.007
SLKESEALPEK 615.83 284119 PTRF 0.06 0.004
SLKESEALPEK 410.89 284119 PTRF 0.12 0.004
Peptides up-regulated in tumor samples
VAPEEHPVLLTEAPLNPK 652.03 60 ACTB 2.32 0.026
MQKEITALAPSTMK 516.94 60 ACTB 2.40 0.032
IWHHTFYNELR 505.92 60 ACTB 2.50 0.024
IMFVDPSLTVR 639.35 10551 AGR2 4.70 0.024
LPQTLSR 407.74 10551 AGR2 5.99 0.021
KLNQALLDLHALGSAR 574.00 2512 FLP 5.93 0.047
PPYTVVYFPVR 669.31 2950 GSTP1 2.64 0.039
VGVNGFGR 403.22 2597 GAPDH 3.67 0.005
GALQNIIPASTGAAK 706.40 2597 GAPDH 7.52 0.009
DNIQGITKPAIR 442.59 8294, 8359, 8364, 8367 HIST1H4A, HIST1H4C, HIST1H4E,
HIST1H4I
2.36 0.001
AGLQFPVGR 472.77 3012, 3013, 3014, 3015, 8329, 8331, 8334,
8337, 92815, 94239, 55766, 85235, 221613
HIST1H2AA, HIST1H2AC, HIST1H2AD,
HIST1H2AE, HIST1H2AH, HIST1H2AI,
HIST1H2AJ, HIST2H2AA3, H2AFJ,
H2AFV, H2AFX, H2AFZ, HIST3H2A
2.52 0.001
TVTAMDVVYALKR 489.61 8294, 8359, 8364, 8367 HIST1H4A, HIST1H4C, HIST1H4E,
HIST1H4I
2.68 0.009
DNIQGITKPAIR 663.38 8294, 8359, 8364, 8367 HIST1H4A, HIST1H4C, HIST1H4E,
HIST1H4I
2.73 0.004
YHTSQSGDEMTSLSEYVSR 726.32 3326 HSP90AB1 3.36 0.002
ALLFIPR 415.27 3326 HSP90AB1 4.50 0.004
SNMDNMFESYINNLRR 668.64 3856 KRT8 2.63 0.041
TKFETEQALR 408.22 3872/3880 KRT17/KRT19 1.78 0.027
LLEGEDAHLTQYK 506.26 3872/3881 KRT17/KRT19 2.67 0.007
VLDELTLAR 515.30 3872/3882 KRT17/KRT19 2.75 0.004
PMFIVNTNVPR 644.35 4282 MIF 21.37 0.000
LRTLNLGGNALDR 706.90 60506 NYX 4.99 0.008
WFYIASAFR 580.80 5005 ORM2 3.08 0.015
ALESPERPFLAILGGAK 590.34 5230 PGK 5.51 0.003
SLPNEEIVQK 578.82 182465 SON 13.52 0.004
GYPTLLWFR 576.81 81567 TXNDC5 3.78 0.032
TLMNLGGLAVAR 608.35 8407 TAGLN2 2.97 0.035
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samples. In order to avoid false positive identifications, more than
twenty MS2 spectra for each MIF and PTRF/cavin-1 peptides
were evaluated manually (Figures S3 and S4 and Table S3).
Changes in PTRF/cavin-1 and MIF expression in NSCLC
samples were validated using immunohistochemistry (IHC) and
western blot analyses. The same samples used for MS/MS
analyses and nine additional samples of adenocarcinoma,
squamous cell carcinoma and normal lung were evaluated for
MIF and PTRF using western blot. Five additional samples of
adenocarcinoma, squamous cell carcinoma and normal lung were
evaluated for MIF and PTRF using IHC. All tumours show
positive staining for MIF and negative staining for PTRF, while all
normal tissues were negative for MIF and positive for PTRF
staining. MIF over-expression in tumor tissues was confirmed both
by IHC and western blot (Figures 3 and 4). On the other hand,
tumor samples confirmed loss of PTRF/cavin-1 expression when
compared with normal lung (Figures 3 and 4) using both
techniques. Pearson’s correlation between Sieve label-free expres-
sion values and western blot quantification was r = 0.723 and
r = 0.754 (p,0.005) for MIF and PTRF/cavin-1 respectively.
We searched in the STRING database for interactomic
connections of MIF and PTRF. In order to minimize the rate of
false positives, we eliminated partners using stringent criteria, and
only experimental protein-protein interactions and pathways from
curated databases were taken into account. PTRF is included in
the RNA transcription pathway, and physically interacts with
TTF1. Other PTRF interactions comprise proteins involved in
transcription regulation and EGFR (Figure 5). MIF is related to
the phenylalanine metabolism pathway, and interacts with p53
and proteins of the COP9 signalosome complex, a complex
involved in various cellular and developmental processes,
including p53 phosphorylation-mediated degradation [19]. Other
interactions comprise proteins related with cell death regulation
and inflammatory process (Figure 6).
Discussion
Proteomics in general and phosphoproteomics in particular are
becoming the preferred methods of protein discovery-based
analyses. The use of label-free, discovery-based approaches may
help discover unexpected biological connections due to the
absence of previous knowledge bias. Bioinformatics tools, such as
gene ontology and interactome analyses, applied on clinical
samples have great potential to identify pathways and molecules
with implication at the therapeutic level and may offer clues to the
genesis of diseases and their underlying molecular alterations.
However, both the technology itself and data analysis tools should
be further refined before their entry into the clinic.
Phosphopeptide enrichment of samples prior to MS analysis
using PIMAC worked reasonably well, as 20% of measured
peptides were phosphorylated. Previous studies have shown an
enrichment of phosphopeptides of approximately 50% using an
IMAC protocol similar to ours on tryptic digest of a mixture of
several reference proteins [20]. Considering that our samples were
very complex and that we did not use any fractionation step,
phosphopeptide enrichment was successful and comparable with
that obtained in previous works [21,22]. However, most of the
spectra showing a phosphate loss presented a poor fragmentation,
and no peptide identification was generated. The use of new
fragmentation techniques, as higher energy collisional dissociation,
improve the quality of fragmentation spectra [23], allowing to
perform large-scale phosphoproteome analysis.
Table 1. Cont.
Peptide m/z GeneID Gene Symbol
Ratio
TvsN P Value
QMEQISQFLQAAER 560.28 8407 TAGLN2 3.31 0.012
DDGLFSGDPNWFPKK 574.94 8407 TAGLN2 3.64 0.020
DDGLFSGDPNWFPK 797.86 8407 TAGLN2 4.78 0.035
LAVNMVPFPR 572.32 203068 TUBB 3.23 0.010
LHFFMPGFAPLTSR 540.95 203068 TUBB 4.53 0.003
Differentially expressed peptides between NSCLC and normal lung samples identified using SIEVE 1.2 software. Peptides presenting different m/z values have been
identified with various charge states.
doi:10.1371/journal.pone.0033752.t001
Figure 2. PTRF/cavin-1 and MIF label-free expression values by SIEVE. Boxplots represent mean and 25th–75th percentile; whiskers
represent minimun and maximun. Measurements were obtained from five different samples in each condition. Kruskall-Wallis test p-values are
shown. AC: Adenocarcinoma; SC: Squamous cell carcinoma; NL: Normal lung.
doi:10.1371/journal.pone.0033752.g002
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Gene ontology analyses of biological process and pathways
showed an increase in categories related to energy production in
cells, such as glycolysis and generation of precursor metabolites
and energy. These differences in energy metabolism between
normal and tumor cells are known as Warburg effect [24]. From
the signaling pathways under-represented in NSCLC tissues,
chemokine- and cytokine-mediated inflammation has been
previously shown to be under-represented in NSCLC [25]. It is
remarkable the over-representation of proteins belonging to
EGFR signaling pathway, in a context where the clinical use of
EGFR inhibitors has become the paradigm of personalized
therapy for NSCLC [26,27,28].
Figure 3. Validation of PTRF/cavin-1 and MIF expression changes using IHC and western blot. a) Western blot of total protein extracted
from indicated samples, using anti-MIF and anti-PTRF/cavin-1 primary antibodies. b) Densitometric analyses of western blot. ImageJ 1.38e software
was employed to measure the intensity of bands. All values in arbitrary units. c) Immunohistochemistry of indicated samples, using anti-MIF and anti-
PTRF/cavin-1 primary antibodies. AC: Adenocarcinoma; SC: Squamous cell carcinoma; NL: Normal lung.
doi:10.1371/journal.pone.0033752.g003
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More than 10% of detected peptides showed a differential
expression between normal and tumor samples. The percentage of
differential peptides was less than 2% when comparing adenocar-
cinoma and lung squamous cell carcinoma samples, but still there
were substantial differences between these two NSCLC histolog-
ical subtypes, as we have previously demonstrated [11].
We were able to validate NSCLC potential biomarkers
identified in shotgun proteomics analyses using IHC and western
blot approaches. MIF (macrophage migration inhibitory factor)
discriminated between normal lung and NSCLC samples. This
well known factor is a proinflammatory cytokine capable of acting
as soluble growth factor, expressed and secreted in response to
mitogens and integrin-mediated signals. MIF protein is involved in
many malignancies, as it promotes cellular transformation, inhibits
cytolytic immune response against tumor cells and promotes
neovascularization [29]. Interactome analyses revealed a close
relation between cell death regulation and MIF, and it is not
surprising that MIF over-expression was described in many types
Figure 4. Validation of PTRF/cavin-1 and MIF expression changes by western blot using a new cohort. Box-Plot graphs showing PTRF
and MIF western blot quantification using ImageJ 1.38e software. All values in arbitrary units. Each Box includes values from nine different samples.
Differences between normal and tumoral samples were p,0.005 in both cases (Kruskall-Wallis test).
doi:10.1371/journal.pone.0033752.g004
Figure 5. PTRF interactome network. A graph of PTRF network built using STRING v9.0 is shown. Different line colours represent the types of
evidence for the association: pink for experiments and blue for databases.
doi:10.1371/journal.pone.0033752.g005
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of cancer, including colorectal, breast, prostate, skin and lung
cancer [30,31], having a major role in the development of tumors
in the central nervous system [32]. Tumors co-expressing MIF and
its membrane receptor (CD74 protein) have increased vascular-
ization [33]. Although there are several molecules that inhibit
enzymatic activity of MIF, its high IC50 has limited its clinical use
so far [34], but new molecules are under current development
[35]. Our results show an increased expression of MIF in NSCLC
samples by label-free proteomics, confirmed by both western blot
and immunohistochemistry.
PTRF (Polimerase I and Transcript Release Factor), also
known as cavin-1, is a protein essential for RNA transcription
[36] and caveolae formation [37]. These invaginations of the cell
surface are associated with processes of vesicular transport,
cholesterol homeostasis, signal transduction [38] and lipolysis
control [39]. Therefore, it is not surprising that PTRF/cavin-1
mutations are associated with congenital generalized lipodystro-
phy, type 4 in humans [40]. PTRF/cavin-1 colocalizes with
caveolin 1 (CAV1) within caveolae [41], and positively modulates
its expression [42]. Interactome analyses suggest that PTRF
harbors unknown functions beyond some recently described
[43,44,45]. Loss of PTRF/cavin-1 expression in prostate cancer
has been related with progression [46], and it has been
demonstrated that its expression decreases the migration of
PTRF/cavin-1-deficient prostate cancer cells [47]. The loss of
PTRF/cavin-1 expression in tumorigenic HBE cells as compared
with normal human bronchial epithelial cells has been proved
recently [48]. Bai and colleagues have reported recently that
PTRF protein was down-regulated in breast cancer cell lines and
breast tumor tissue, and that down-regulation of PTRF in breast
cancer cells was associated with the promoter methylation [49].
PTRF/cavin-1 phosphorylated species have been described in
cells that over-express EGFR, which suggests a function in this
signaling pathway [50]. Our label-free proteomics results indicate
that PTRF expression is lost in NSCLC samples. These results
were confirmed using both western blot and immunohistochem-
ical staining. This is the first study showing PTRF/cavin-1 loss of
expression in NSCLC tumor tissue at the protein level. This loss
of expression, along with PTRF-EGFR interaction and EGFR
pathway deregulation in NSCLC samples, suggests a role of
PTRF in NSCLC development.
Our work demonstrates that it is possible to identify potential
biomarkers using a label-free differential proteomics strategy on
real clinical samples. We identified several differential markers,
two of which were validated by alternative classical proteomic
methods. Moreover, we show that gene ontology and interaction
analyses can identify pathways and processes altered on tumor
tissue, which may provide clues to the genesis of the disease and its
underlying molecular alterations, and could be susceptible to
therapeutic intervention. In this sense, this work indicates that
PTRF role in NSCLC and its relationship with EGFR pathway
deserves further exploration.
Figure 6. MIF interactome network. A graph of MIF network built using STRING v9.0 is shown. Different line colours represent the types of
evidence for the association: pink for experiments and blue for databases.
doi:10.1371/journal.pone.0033752.g006
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Supporting Information
Figure S1 Analysis of differences in GO Molecular
Function between NSCLC and normal lung. Comparison
of number of proteins assigned to each GO pathway category.
Normal tissue sample categories are represented as fold-change in
relation to this category. Statistical significance is tested using the
binomial test. Only significant categories (p,0.05) are shown.
(TIF)
Figure S2 Analysis of differences in GO Biological
Process between NSCLC and normal lung. Comparison
of number of proteins assigned to each GO pathway category.
Normal tissue sample categories are represented as fold-change in
relation to this category. Statistical significance is tested using the
binomial test. Only significant categories (p,0.05) are shown.
(TIF)
Figure S3 Fragmentation spectra from PTRF SLKE-
SEALPEK tryptic peptide. Diagram shows fragment ions
corresponding to main fragmentation series (b-amino and y-
carboxy). * indicates water loss; 2+, doubly charged fragment.
Parental ion is marked with an arrow.
(TIF)
Figure S4 Fragmentation spectra from MIF
PMFIVNTNVPR tryptic peptide. Diagram shows fragment
ions corresponding to main fragmentation series (b-amino and y-
carboxy). * indicates water loss. Parental ion is marked with an
arrow.
(TIF)
Table S1 Gene Ontology analyses performed with
PANTHER. Normal lung protein list was used as reference list.
(PDF)
Table S2 SIEVE label-free quantification. Data obtained
from SIEVE analyses, including relative expression values.
(PDF)
Table S3 PTRF and MIF MS2 spectra.
(PDF)
Table S4 Peptide Mass Fingerprint and Protein Identi-
fication settings.
(DOC)
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